BMS Sotyktu shows sustained efficacy in psoriatic arthritis at two years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. CSX
6. LRCX
7. LVS
8. SAP
9. SPCX
10. SPY

Go back to BMS Sotyktu shows sustained efficacy in psoriatic arthritis at two years

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

September 17, 2026 6:59 AM EDT

Results from the POETYK PsA-2 open-label extension demonstrated robust response rates in patients treated with Sotyktu, with clinical responses continuing to improve through year one and maintained through year two

Two-year data build on the proven efficacy and safety profile of Sotyktu as the only approved tyrosine kinase 2 (TYK2) inhibitor for adults with psoriatic arthritis

PRINCETON, N.J.--(BUSINESS WIRE)--... More